These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33708893)

  • 41. Sensitivity of MLL-rearranged AML cells to all-trans retinoic acid is associated with the level of H3K4me2 in the RARα promoter region.
    Sakamoto K; Imamura T; Yano M; Yoshida H; Fujiki A; Hirashima Y; Hosoi H
    Blood Cancer J; 2014 Apr; 4(4):e205. PubMed ID: 24769646
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
    Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
    J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Knockdown of let-7b in leukemia associated macrophages inhibit acute myeloid leukemia progression.
    Tian C; Li Y; Si J; Kang J; Chen Z; Nuermaimaiti R; Wang Y; Yu Y; Zhao Z; Wang X; Zhang Y; Zhao H; Yang H; You MJ; Zheng G; Wang L
    Hematol Oncol; 2023 Aug; 41(3):510-519. PubMed ID: 36579468
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia.
    Prange KHM; Mandoli A; Kuznetsova T; Wang SY; Sotoca AM; Marneth AE; van der Reijden BA; Stunnenberg HG; Martens JHA
    Oncogene; 2017 Jun; 36(23):3346-3356. PubMed ID: 28114278
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia.
    Ghisi M; Kats L; Masson F; Li J; Kratina T; Vidacs E; Gilan O; Doyle MA; Newbold A; Bolden JE; Fairfax KA; de Graaf CA; Firth M; Zuber J; Dickins RA; Corcoran LM; Dawson MA; Belz GT; Johnstone RW
    Cancer Cell; 2016 Jul; 30(1):59-74. PubMed ID: 27374225
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TIGIT blockade repolarizes AML-associated TIGIT
    Brauneck F; Fischer B; Witt M; Muschhammer J; Oelrich J; da Costa Avelar PH; Tsoka S; Bullinger L; Seubert E; Smit DJ; Bokemeyer C; Ackermann C; Wellbrock J; Haag F; Fiedler W
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36549780
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hoxa9 influences the phenotype but not the incidence of Mll-AF9 fusion gene leukemia.
    Kumar AR; Hudson WA; Chen W; Nishiuchi R; Yao Q; Kersey JH
    Blood; 2004 Mar; 103(5):1823-8. PubMed ID: 14615372
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.
    Zhao X; Chen A; Yan X; Zhang Y; He F; Hayashi Y; Dong Y; Rao Y; Li B; Conway RM; Maiques-Diaz A; Elf SE; Huang N; Zuber J; Xiao Z; Tse W; Tenen DG; Wang Q; Chen W; Mulloy JC; Nimer SD; Huang G
    Blood; 2014 Mar; 123(11):1729-38. PubMed ID: 24449215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.
    Kim WI; Matise I; Diers MD; Largaespada DA
    Blood; 2009 Jan; 113(5):1086-96. PubMed ID: 18952898
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular pathogenesis of disease progression in MLL-rearranged AML.
    Kotani S; Yoda A; Kon A; Kataoka K; Ochi Y; Shiozawa Y; Hirsch C; Takeda J; Ueno H; Yoshizato T; Yoshida K; Nakagawa MM; Nannya Y; Kakiuchi N; Yamauchi T; Aoki K; Shiraishi Y; Miyano S; Maeda T; Maciejewski JP; Takaori-Kondo A; Ogawa S; Makishima H
    Leukemia; 2019 Mar; 33(3):612-624. PubMed ID: 30209403
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome.
    Stavropoulou V; Kaspar S; Brault L; Sanders MA; Juge S; Morettini S; Tzankov A; Iacovino M; Lau IJ; Milne TA; Royo H; Kyba M; Valk PJM; Peters AHFM; Schwaller J
    Cancer Cell; 2016 Jul; 30(1):43-58. PubMed ID: 27344946
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High BRE expression predicts favorable outcome in adult acute myeloid leukemia, in particular among MLL-AF9-positive patients.
    Noordermeer SM; Sanders MA; Gilissen C; Tönnissen E; van der Heijden A; Döhner K; Bullinger L; Jansen JH; Valk PJ; van der Reijden BA
    Blood; 2011 Nov; 118(20):5613-21. PubMed ID: 21937695
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Learning from mouse models of MLL fusion gene-driven acute leukemia.
    Schwaller J
    Biochim Biophys Acta Gene Regul Mech; 2020 Aug; 1863(8):194550. PubMed ID: 32320749
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phosphoinositide-dependent kinase 1 regulates leukemia stem cell maintenance in MLL-AF9-induced murine acute myeloid leukemia.
    Hu T; Li C; Zhang Y; Wang L; Peng L; Cheng H; Wang W; Chu Y; Xu M; Cheng T; Yuan W
    Biochem Biophys Res Commun; 2015 Apr; 459(4):692-8. PubMed ID: 25769952
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Role of Vascular Niche of Bone Marrow in the Development of MLL-AF9 Induced Acute Myclaid Leukemia].
    Zhao M; Gong YM; Yang WZ; Cheng H; Cheng T
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):318-326. PubMed ID: 30998132
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.
    Jiang X; Huang H; Li Z; He C; Li Y; Chen P; Gurbuxani S; Arnovitz S; Hong GM; Price C; Ren H; Kunjamma RB; Neilly MB; Salat J; Wunderlich M; Slany RK; Zhang Y; Larson RA; Le Beau MM; Mulloy JC; Rowley JD; Chen J
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19397-402. PubMed ID: 23132946
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Functional Niche Competition Between Normal Hematopoietic Stem and Progenitor Cells and Myeloid Leukemia Cells.
    Glait-Santar C; Desmond R; Feng X; Bat T; Chen J; Heuston E; Mizukawa B; Mulloy JC; Bodine DM; Larochelle A; Dunbar CE
    Stem Cells; 2015 Dec; 33(12):3635-42. PubMed ID: 26388434
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model.
    Sontakke P; Carretta M; Jaques J; Brouwers-Vos AZ; Lubbers-Aalders L; Yuan H; de Bruijn JD; Martens AC; Vellenga E; Groen RW; Schuringa JJ
    Leukemia; 2016 Oct; 30(10):2064-2073. PubMed ID: 27125308
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aggressive leukemia driven by MLL-AF9.
    Stavropoulou V; Peters AHFM; Schwaller J
    Mol Cell Oncol; 2018; 5(3):e1241854. PubMed ID: 30250880
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Generation of a MLL-AF9-specific stem cell model of acute monocytic leukemia.
    Chiew MY; Boo NY; Voon K; Cheong SK; Leong PP
    Leuk Lymphoma; 2017 Jan; 58(1):162-170. PubMed ID: 27185517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.